Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The evolution of resistance and tolerance as cancer defences.
Thomas F, Giraudeau M, Gouzerh F, Boutry J, Renaud F, Pujol P, Tasiemski A, Bernex F, Maraver A, Bousquet E, Dormont L, Osterkamp J, Roche B, Hamede R, Ujvari B. Thomas F, et al. Among authors: bousquet e. Parasitology. 2020 Mar;147(3):255-262. doi: 10.1017/S0031182019001501. Epub 2019 Dec 11. Parasitology. 2020. PMID: 31727197 Free PMC article.
RIP140 regulates transcription factor HES1 oscillatory expression and mitogenic activity in colon cancer cells.
Sfeir N, Kajdan M, Jalaguier S, Bonnet S, Teyssier C, Pyrdziak S, Yuan R, Bousquet E, Maraver A, Bernex F, Pirot N, Boissière-Michot F, Castet-Nicolas A, Lapierre M, Cavaillès V. Sfeir N, et al. Among authors: bousquet e. Mol Oncol. 2024 Jun;18(6):1510-1530. doi: 10.1002/1878-0261.13626. Epub 2024 Mar 8. Mol Oncol. 2024. PMID: 38459621 Free PMC article.
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y. Mancini M, et al. Among authors: bousquet e. EMBO Mol Med. 2018 Feb;10(2):294-308. doi: 10.15252/emmm.201708076. EMBO Mol Med. 2018. PMID: 29212784 Free PMC article.
The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.
Calvayrac O, Mazières J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, Guibert N, Lusque A, Cadranel J, Mathiot N, Savina A, Pradines A, Favre G. Calvayrac O, et al. Among authors: bousquet e. EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm.201606646. EMBO Mol Med. 2017. PMID: 28003335 Free PMC article.
[An unusual mediastinal mass].
Bousquet E, Pontier S, Hermant C, Rouquette I, Meyer N, Didier A, Mazieres J. Bousquet E, et al. Rev Mal Respir. 2014 Sep;31(7):624-7. doi: 10.1016/j.rmr.2013.11.004. Epub 2013 Dec 11. Rev Mal Respir. 2014. PMID: 25239585 French.
RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.
Calvayrac O, Pradines A, Raymond-Letron I, Rouquette I, Bousquet E, Lauwers-Cances V, Filleron T, Cadranel J, Beau-Faller M, Casanova A, Milia J, Favre G, Mazières J. Calvayrac O, et al. Among authors: bousquet e. Clin Cancer Res. 2014 Dec 15;20(24):6541-50. doi: 10.1158/1078-0432.CCR-14-0506. Epub 2014 Oct 15. Clin Cancer Res. 2014. PMID: 25320360
[New targets and new drugs in thoracic oncology].
Rouviere D, Bousquet E, Pons E, Milia JD, Guibert N, Mazieres J. Rouviere D, et al. Among authors: bousquet e. Rev Mal Respir. 2015 Oct;32(8):867-76. doi: 10.1016/j.rmr.2015.02.091. Epub 2015 Jun 12. Rev Mal Respir. 2015. PMID: 26076869 Review. French.
191 results